Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Stoke Therapeutics Inc's Business Segments
Stoke Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Global Development Activity
Total Revenue
$ 6
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Global Development Activity64.7%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Global Development Activity | $ 4 | 64.7% |
Revenue by Product & Service Category - FY
- Global Development Activity64.7%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Global Development Activity | $ 4 | 64.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Global Development Activity64.7%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Global Development Activity | $ 4 | 64.7% |
Description of Stoke Therapeutics Inc
Stoke Therapeutics Inc is a biotechnology company that specializes in developing innovative therapies for severe genetic diseases. The company was founded in 2018 and is based in Bedford, Massachusetts.
Stoke Therapeutics focuses on developing a novel drug discovery platform called Targeted Augmentation of Nuclear Gene Output (TANGO). This platform utilizes antisense oligonucleotides (ASOs) to selectively increase the expression of specific genes that are impacted by loss-of-function mutations. The company's primary goal is to develop therapies that address the underlying cause of diseases rather than just alleviating their symptoms.
One of the key aspects of Stoke's approach is to selectively increase the expression of a gene rather than suppress it. This is achieved by targeting a noncoding RNA molecule called the antisense transcript, which prevents the target gene from being expressed. By increasing the expression of the target gene, Stoke's therapies aim to restore normal cellular function and improve disease outcomes.
Stoke Therapeutics has initially focused on developing treatments for genetic diseases that are caused by a haploinsufficiency mechanism, meaning that a loss-of-function mutation in one copy of a gene leads to the disease. These diseases include Dravet syndrome, a severe form of epilepsy, and autosomal dominant optic atrophy (ADOA), a progressive eye disorder.
The company's lead product candidate, STK-001, is being developed for the treatment of Dravet syndrome. STK-001 is an ASO designed to increase the expression of the SCN1A gene, which is mutated in Dravet syndrome patients. Preclinical studies have shown promising results, demonstrating increased expression of the SCN1A gene and improved disease phenotypes in animal models.
Stoke Therapeutics has also developed a pipeline of other potential therapies using the TANGO platform. These include candidates for other genetic diseases, such as genetic forms of epilepsy and single-gene disorders. The company aims to bring these therapies to clinical trials in the coming years.
In addition to its drug discovery efforts, Stoke Therapeutics has established collaborations with leading academic institutions and organizations in the field of genetic diseases. These collaborations aim to leverage external expertise and resources to accelerate the development of novel therapies.
Overall, Stoke Therapeutics is a pioneering biotechnology company that is developing innovative therapies utilizing its TANGO platform for severe genetic diseases. The company's approach of selectively increasing the expression of target genes has the potential to transform the treatment landscape for these diseases and improve the lives of patients and their families.
Stoke Therapeutics focuses on developing a novel drug discovery platform called Targeted Augmentation of Nuclear Gene Output (TANGO). This platform utilizes antisense oligonucleotides (ASOs) to selectively increase the expression of specific genes that are impacted by loss-of-function mutations. The company's primary goal is to develop therapies that address the underlying cause of diseases rather than just alleviating their symptoms.
One of the key aspects of Stoke's approach is to selectively increase the expression of a gene rather than suppress it. This is achieved by targeting a noncoding RNA molecule called the antisense transcript, which prevents the target gene from being expressed. By increasing the expression of the target gene, Stoke's therapies aim to restore normal cellular function and improve disease outcomes.
Stoke Therapeutics has initially focused on developing treatments for genetic diseases that are caused by a haploinsufficiency mechanism, meaning that a loss-of-function mutation in one copy of a gene leads to the disease. These diseases include Dravet syndrome, a severe form of epilepsy, and autosomal dominant optic atrophy (ADOA), a progressive eye disorder.
The company's lead product candidate, STK-001, is being developed for the treatment of Dravet syndrome. STK-001 is an ASO designed to increase the expression of the SCN1A gene, which is mutated in Dravet syndrome patients. Preclinical studies have shown promising results, demonstrating increased expression of the SCN1A gene and improved disease phenotypes in animal models.
Stoke Therapeutics has also developed a pipeline of other potential therapies using the TANGO platform. These include candidates for other genetic diseases, such as genetic forms of epilepsy and single-gene disorders. The company aims to bring these therapies to clinical trials in the coming years.
In addition to its drug discovery efforts, Stoke Therapeutics has established collaborations with leading academic institutions and organizations in the field of genetic diseases. These collaborations aim to leverage external expertise and resources to accelerate the development of novel therapies.
Overall, Stoke Therapeutics is a pioneering biotechnology company that is developing innovative therapies utilizing its TANGO platform for severe genetic diseases. The company's approach of selectively increasing the expression of target genes has the potential to transform the treatment landscape for these diseases and improve the lives of patients and their families.
Stoke Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases, particularly those involving the central nervous system. The company leverages its proprietary technology platform to address diseases caused by loss of function mutations, aiming to restore protein expression. Below is an extensive description of the segments, products, and services offered by Stoke Therapeutics.
Segments
1. Genetic Disease Therapeutics:
- Stoke Therapeutics specializes in creating therapies targeting genetic disorders, emphasizing conditions where a specific protein is underexpressed due to genetic mutations.
- The companys research primarily revolves around conditions linked to the nervous system and other critical systems where protein function is essential for cellular and organ health.
2. RNA Modulation:
- The company utilizes RNA modulation techniques to enhance protein expression, specifically through mechanisms like exon skipping, which selectively excludes parts of the gene that are not functional due to mutations.
- This approach enables the production of functional proteins, providing a potential therapeutic pathway for diseases previously deemed untreatable.
Products
1. STK-001:
- Overview: This is one of Stokes leading product candidates, developed for the treatment of Dravet syndrome, a severe form of epilepsy that begins in infancy and is associated with high mortality rates and morbidity.
- Mechanism: STK-001 aims to modulate the expression of the SCN1A gene, which is critical in the development and function of neurons. By enhancing the production of a functional sodium channel protein, this treatment may reduce seizure frequency.
2. Pipeline Candidates:
- Stoke has an expanding pipeline that includes other candidates targeting various genetic diseases, particularly those affecting the nervous system.
- Additional candidates may focus on diseases like Angelman syndrome and other conditions resulting from loss of function mutations.
Services
1. Preclinical and Clinical Development:
- Stoke Therapeutics is engaged in extensive preclinical research to validate the efficacy and safety of its product candidates. This involves rigorous testing in cellular models and animal studies to ascertain the potential impact of therapies on target diseases.
- Once promising candidates advance, Stoke conducts clinical trials to evaluate their effectiveness in human subjects, including Phase 1 and Phase 2 trials to assess safety and dosage effectiveness.
2. Partnerships and Collaborations:
- Stoke Therapeutics actively seeks partnerships with other research institutions, biotech companies, and pharmaceutical firms to leverage additional expertise, resources, and technologies in developing their product candidates.
- Collaborations may focus on advancing existing therapies, discovering new applications for their platform, or providing funding support for further research.
3. Research and Development:
- The companys core competency lies in R&D, where they focus on refining their RNA modulation technology and exploring new therapeutic targets.
- Stoke invests in understanding disease mechanisms, patient populations, and the genetic underpinnings of various conditions to guide their pipeline development.
Conclusion
Stoke Therapeutics Inc. operates at the intersection of genetic research and innovative therapy development, leveraging its proprietary RNA modulation technology to address severe genetic disorders. Through its product pipeline, notably STK-001, and commitment to rigorous R&D and collaboration, the company is poised to make significant impacts in the treatment of conditions linked to underexpressed proteins, with a strong focus on the central nervous system.
Segments
1. Genetic Disease Therapeutics:
- Stoke Therapeutics specializes in creating therapies targeting genetic disorders, emphasizing conditions where a specific protein is underexpressed due to genetic mutations.
- The companys research primarily revolves around conditions linked to the nervous system and other critical systems where protein function is essential for cellular and organ health.
2. RNA Modulation:
- The company utilizes RNA modulation techniques to enhance protein expression, specifically through mechanisms like exon skipping, which selectively excludes parts of the gene that are not functional due to mutations.
- This approach enables the production of functional proteins, providing a potential therapeutic pathway for diseases previously deemed untreatable.
Products
1. STK-001:
- Overview: This is one of Stokes leading product candidates, developed for the treatment of Dravet syndrome, a severe form of epilepsy that begins in infancy and is associated with high mortality rates and morbidity.
- Mechanism: STK-001 aims to modulate the expression of the SCN1A gene, which is critical in the development and function of neurons. By enhancing the production of a functional sodium channel protein, this treatment may reduce seizure frequency.
2. Pipeline Candidates:
- Stoke has an expanding pipeline that includes other candidates targeting various genetic diseases, particularly those affecting the nervous system.
- Additional candidates may focus on diseases like Angelman syndrome and other conditions resulting from loss of function mutations.
Services
1. Preclinical and Clinical Development:
- Stoke Therapeutics is engaged in extensive preclinical research to validate the efficacy and safety of its product candidates. This involves rigorous testing in cellular models and animal studies to ascertain the potential impact of therapies on target diseases.
- Once promising candidates advance, Stoke conducts clinical trials to evaluate their effectiveness in human subjects, including Phase 1 and Phase 2 trials to assess safety and dosage effectiveness.
2. Partnerships and Collaborations:
- Stoke Therapeutics actively seeks partnerships with other research institutions, biotech companies, and pharmaceutical firms to leverage additional expertise, resources, and technologies in developing their product candidates.
- Collaborations may focus on advancing existing therapies, discovering new applications for their platform, or providing funding support for further research.
3. Research and Development:
- The companys core competency lies in R&D, where they focus on refining their RNA modulation technology and exploring new therapeutic targets.
- Stoke invests in understanding disease mechanisms, patient populations, and the genetic underpinnings of various conditions to guide their pipeline development.
Conclusion
Stoke Therapeutics Inc. operates at the intersection of genetic research and innovative therapy development, leveraging its proprietary RNA modulation technology to address severe genetic disorders. Through its product pipeline, notably STK-001, and commitment to rigorous R&D and collaboration, the company is poised to make significant impacts in the treatment of conditions linked to underexpressed proteins, with a strong focus on the central nervous system.